Introduction
Large granular lymphocyte (LGL) leukemia is a clonal disease representing a spectrum of biologically distinct lymphoproliferative diseases originating either from mature CD3 þ T cells or CD3 À natural killer (NK) cells [1] . Both CD3 þ and CD3 À LGLs function as cytotoxic lymphocytes. The 2008 World Health Classification of mature T-cell and NK-cell neoplasms continues to distinguish T-cell LGL leukemia (T-LGL leukemia) from aggressive NK-cell leukemia based on their unique molecular and clinical features [2] . Furthermore, a new provisional entity of chronic lymphoproliferative disorder of NK cells (also known as chronic NK cell lymphocytosis or chronic NK-LGL leukemia) was created to distinguish it from much more aggressive NK-cell leukemia [2] . The T-cell form of LGL leukemia was first described in 1985 as a clonal disorder, including blood, marrow and spleen [3] . One of these initial patients had rheumatoid arthritis (RA) and indeed had been characterized previously as having Felty's syndrome. Subsequently, RA was recognized as a characteristic finding of T-LGL leukemia [4] . RA is only rarely associated with the NK type of LGL leukemia; consequently, this article will focus on the T-cell form of LGL leukemia. LGL leukemia is diagnosed in the clinical context of cytopenia, lymphocytosis, splenomegaly and autoimmune conditions such as RA.
LGL leukemia patients show an excess of LGLs, more than 0.5Â10 9 /l, with CD3 þ CD8 þ CD57 þ immunophenotype. Furthermore, a main criterion for T-LGL leukemia is the detection of a clonal T-cell receptor (TCR) rearrangement with a typical phenotype of TCR-ab.
First described in 1924, Felty's syndrome, a specific subcategory of RA featuring the co-occurrence of RA, neutropenia and splenomegaly [5] , is frequently associated with LGL leukemia [6] . In fact, approximately 30-40% of Felty's syndrome patients have peripheral blood expansions of LGLs [7] . The clinical presentation in Felty's syndrome patients closely resembles that in LGL leukemia patients with neutropenia and RA [6] . Importantly, patients with Felty's syndrome may have a clonal proliferation of LGLs characterized by TCR rearrangements [8] . Due to the prevalence of the immunogenic marker HLA-DR4 in both diseases [9] [10] [11] , it has been suggested that Felty's syndrome and LGL leukemia with RA are part of a single disease process [12] .
Purpose of review
Patients with chronic large granular lymphocyte (LGL) leukemia often have rheumatoid arthritis (RA), neutropenia and splenomegaly, thereby resembling the manifestations observed in patients with Felty's syndrome, which is a rare complication of RA characterized by neutropenia and splenomegaly. Both entities have similar clinical and laboratory presentation, as well as a common genetic determinant, HLA-DR4, indicating they may be part of the same disease spectrum. This review paper seeks to discuss the underlying pathogenesis and therapeutic algorithm of RA, neutropenia and splenomegaly in the spectrum of LGL leukemia and Felty's syndrome.
Recent findings
We hypothesize that there may be a common pathogenic mechanism between LGL leukemia and typical Felty's syndrome. Phenotypic and functional data have strongly suggested that CD3 þ LGL leukemia is antigen-activated. Aberrations in the T-cell repertoire with the emergence of oligoclonal/clonal lymphoid populations have been found to play a pivotal role in pathogenesis of RA. The biologic properties of the pivotal T cell involved in RA pathogenesis are remarkably similar to those in leukemic LGL. Rheumatoid arthritis in large granular lymphocyte leukemia and Felty's syndrome Chronic LGL leukemia is known to be associated with a wide spectrum of autoimmune disorders. RA is the most common autoimmune disease associated with LGL leukemia in the western world [12] [13] [14] . RA is mostly diagnosed prior to the onset of LGL leukemia [15 ] . RA is present in 11-36% of patients with LGL leukemia [1,15 ,16] , compared to its presence in 0.5-1% of the adult population worldwide [17] . Notably, Asian patients with LGL leukemia were around seven times less likely than western patients to develop RA [18 ] . Chronic activation by an exogenous antigen such as virus or endogenous autoantigen has been proposed as a possible initial trigger leading to an expansion of LGLs [19] . It has also been suggested that T-LGL leukemia could represent an autoimmune disorder caused by chronic antigenic stimulation leading to extreme expansion of only one clone of CD8 þ cytotoxic T cells [20, 21] . An association of T-LGL leukemia with several different autoimmune conditions supports this hypothesis. Interestingly, RA is a chronic inflammatory disease in which T cells play an essential role in joint destruction. As a rare extra-articular manifestation of RA, Felty's syndrome occurs in less than 1% of RA patients [22] . The mean duration of arthritis is 10-15 years prior to the onset of neutropenia and splenomegaly [23] . Felty's syndrome is clinically characterized by severe joint destruction contrasting with moderate or absent joint inflammation and severe extra-articular disease, including a high frequency of rheumatoid nodules, lymphadenopathy, hepatomegaly, vasculitis, leg ulcers, Sjö gren's syndrome and pulmonary fibrosis [15 ,22] . Articular involvement is usually significantly more severe in patients with Felty's syndrome than in typical RA, with regard to the extent of synovitis and clinical and radiographic deformity [22] .
Neutropenia in large granular lymphocyte leukemia and Felty's syndrome
Neutropenia is the most common finding in LGL leukemia, occurring in 70-80% patients [1, 24] . Neutropeniainduced infections are indications for seeking medical attention in patients with LGL leukemia and Felty's syndrome. Interestingly, neutropenia is less prevalent in Asian LGL leukemia patients; instead, pure red cell aplasia (PRCA), which is caused by cytotoxic activity of leukemic LGLs against erythroid progenitors in marrow [25] , is the most common complication in Asian LGL leukemia patients [18 ] . These findings suggested that differential genetic backgrounds and immune insults might render differential susceptibilities toward clinical manifestations in LGL leukemia [18 ] .
Neutropenia in LGL leukemia may be caused by survival (enhanced neutrophil destruction) and proliferation defects (deregulated neutrophil production), which can be mediated by humoral and cell-mediated mechanisms, respectively [26, 27 ] . Neutrophil production defects do not appear to be prominent in LGL leukemia and Felty's syndrome based on the observations of mild hypercellularity with left-shifted myeloid maturation in marrow [28, 29] . Production of immune complexes can result in decreased neutrophil survival, as can production of soluble Fas ligand [30, 31] . These humoral and cellmediated pathways induce granulocytic apoptosis through independent intracellular mechanisms that are not mutually exclusive and may be observed concurrently in individual patients with either LGL leukemia or Felty's syndrome. Indeed, immunosuppression is often effective in alleviating neutropenia in patients with LGL leukemia and Felty's syndrome [1, 15 ] , giving insight into the nature of aberrant immune response in these two entities contributing to the pathogenesis of neutropenia. Clinical response in LGL leukemia is often associated with reduction in levels of circulating Fas ligand [31] .
Splenomegaly in large granular lymphocyte leukemia and Felty's syndrome
Mild-to-moderate splenomegaly is seen in 20-60% of LGL leukemia patients [30, 32] . Diffuse infiltration of red splenic pulp by leukemic LGLs with frequent presence of reactive germinal centers is a characteristic finding in T-LGL leukemia [33] . Splenomegaly is also a diagnostic hallmark of Felty's syndrome, ranging from mild to massive on imaging [22] . The structural basis for splenomegaly in Felty's syndrome is predominantly an increase in the red pulp, with associated sinus hyperplasia and an increased macrophage population [34] . Notably, the degree of splenomegaly bears no relationship to the degree of hematological abnormalities, including neutropenia in both entities [1, 35] .
Pathogenesis of large granular lymphocyte leukemia and Felty's syndrome
Aberrations in the T-cell repertoire with the emergence of oligoclonal/clonal lymphoid populations have been found to play a pivotal role in the pathogenesis of both LGL leukemia and RA [20, 36] . There are remarkable
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Key points
Large granular lymphocyte (LGL) leukemia/ rheumatoid arthritis and Felty's syndrome are part of the same disease.
LGL leukemia/rheumatoid arthritis and Felty's syndrome share similarity in clinical presentation, immunologic, pathologic, and genetic features. Low dose of immunosuppressive treatment is effective in both patients with LGL leukemia and Felty's syndrome.
phenotypic and functional similarities noted when comparing findings seen in leukemic LGL to those observed in the clonally expanded lymphoid subset in RA. A minor difference is that LGLs from patients with RA usually co-express CD3 and CD8, whereas co-expression of CD4 and CD8 in LGL leukemia is less common. A major difference appears to be that there is a dominant clone detected in LGL leukemia as manifested by markedly increase numbers of LGLs in the periphery, whereas the clonal size of individual T-cell clones observed in typical RA is small. Importantly, LGL leukemia and RA with LGL expansion share the following features in common: clonal expansion of unusual T cells of an effector and/or memory-effector phenotype, being CD3 þ , CD28 À , CD57 þ [37] [38] [39] ; expression of inhibitory and activating NK receptors on LGLs [40, 41] ; constitutive overexpression of cytotoxic effector molecules, such as perforin, soluble granzymes and Fas ligand [42] [43] [44] ; constitutive production of proinflammatory chemokines such as RANTES, macrophage inflammatory protein (MIP)-1a, MIP-1b and IL-8 [45, 46] ; and dysregulated apoptosis characterized by high levels of both Fas receptor and Fas ligand on LGLs but resistance to Fas-mediated death [47, 48] .
Patients with T-LGL leukemia or RA can exhibit substantial expansion of CD8 þ T cells. These CD8 þ T cells can display oligoclonality in the peripheral blood and synovial fluid of RA patients [49] [50] [51] [52] . The antigen driving the expansion of these CD8 þ clones in RA is not known. Using tetramer staining, one study demonstrated Epstein-Barr virus (EBV)-specific CD8 þ T cells in synovial fluid from RA patients. However, these findings were not restricted to RA as there was also an enrichment of these cells in synovial fluid from patients with osteoarthritis and psoriatic arthritis [53] .
Many lines of evidence suggest that clonal expansion of leukemic
LGLs may be antigen-driven, perhaps as a result of yet unknown viral antigen [54] [55] [56] [57] [58] [59] . Serologic findings in LGL leukemia patients are suggestive of infection with members of the HTLV (human T-lymphotropic virus type I)/BLV (bovine leukemia virus) genus of retroviruses. Twenty-one percent of LGL leukemia sera are reactive in a HTLV-I ELISA compared to 0.17% of normal blood donors [59] . In western blot testing against HTLV-I viral lysate, LGL leukemia sera show a similar cross reactivity pattern as seen when testing HTLV-II or BLV-positive sera, that is, reactivity to gag p24 and env p21e [39] . Similar antibody reactivity to env p21e has been observed in sera from patients with typical RA [60] . Further work has shown that this p21e reactivity is directed at a 34 amino acid fragment designated BA21 [54, 61] . These results raise the possibility that exposure to a protein with homology to BA21 may be a common inciting stimulus in both LGL leukemia and typical RA. Collectively, the biologic features of the LGL expansion involved in RA pathogenesis are remarkably similar to those for leukemic LGL.
Treatment of large granular lymphocyte leukemia and Felty's syndrome
The majority of patients with LGL leukemia have a clinically indolent course with a median survival time over 10 years. The most common indications for therapy include recurrent infections due to severe neutropenia, anemia, or less frequently, symptomatic splenomegaly and severe B symptoms [15 ,32] . Systemic immunosuppressive treatment is considered to be the most appropriate form of treatment for both LGL leukemia and Felty's syndrome. First-line, single-agent therapy with low-dose methotrexate (MTX; 10 mg/m 2 per week), cyclophosphamide (50-100 mg orally daily), and cyclosporine A (5-10 mg/kg per day) can control symptoms and cytopenias in approximately 50-60% of LGL leukemia patients [15 ,62-64] , but this approach is not curative. Neutropenia of Felty's syndrome can be effectively treated with disease-modifying antirheumatic drugs (DMARDs), the widest experience being with MTX [65] . Low-dose oral pulse therapy of MTX results in improvement in most Felty's syndrome patients [66, 67] . It is recommended that 4 months of treatment be given before a decision is made to change to an alternative agent because of no response [15 ] . Responders usually require indefinite therapy to prevent relapses. Therapy with low-dose MTX can control both
LGL leukemia and RA [15 ,62] . Cyclosporine A is sometimes used as an initial therapy; however, toxicities of long-term treatment are usually greater than the sideeffects of MTX or cyclophosphamide. Upon achieving best response, the dose of cyclosporine A should be tapered down to obtain the lowest effective maintenance dose [68] . Corticosteroids as monotherapy appear less effective than MTX, cyclosporine A or cyclophosphamide. However, in combination with other immunosuppressants, steroids may improve B symptoms and hematologic features more quickly [15 ,32] . Hematopoietic growth factors [granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF)] have also been used successfully as first-line monotherapy for neutropenia or as a supportive treatment together with immunosuppressive therapy [69, 70] . It is noteworthy that correction of cytopenias with cyclosporine therapy may be achieved without reduction of the clone [68] . Complete normalization of the neutrophil count is not necessary for significant clinical improvement [15 ] .
Patients with LGL leukemia who fail first-line therapy may benefit from second-line therapy with nucleoside analogues, including fludarabine, 2 0 -deoxycoformycine and 2-chloroxyadenosine [71] . The frequent expression of CD52 on malignant LGLs supports the potential efficacy of utilization of targeted therapy with a humanized anti-CD52 antibody (alemtuzumab) in T-LGL leukemia patients [72] . Recently, there has been a growing interest in the biologic agent rituximab in the treatment of Felty's syndrome [73] [74] [75] . Rituximab, a monoclonal antibody specific for human CD20, which recognizes and depletes CD20 þ B lymphocytes, led to a sustained neutrophil response and marked symptomatic improvement, as evidenced by decreased size of rheumatoid nodules and better pain control, in a subset of Felty's syndrome patients [73] [74] [75] .
Splenectomy has been used for therapy of both LGL leukemia and Felty's syndrome and has been beneficial for some patients in both entities. Splenectomy can have a favorable impact on refractory and symptomatic cytopenias in patients with LGL leukemia [76, 77] and can result in an immediate improvement of neutropenia in 80% of the Felty's syndrome patients, with decreased infection rate [65] . Splenectomy can also relieve the gastrointestinal-related symptoms of nausea, early satiety and pain related to splenomegaly [76] . However, the procedure is not curative.
Response to treatment in LGL leukemia must be determined by periodic clinical and blood count assessments [15 ] . The primary response criteria are defined using blood count results 4 months after starting therapy. Hematological complete response (CR) is defined as the complete normalization of blood counts (hemoglobin >12 g/dl, platelets >150 Â 10 9 /l, absolute neutrophil count >1.5 Â 10 9 /l and lymphocytosis <4 Â 10 9 /l), and circulating LGLs in the normal range (0.25 Â 10 9 /l) [15 ] . Complete molecular remission is determined by the disappearance of the T-cell clone [15 ] .
Conclusion
We initially described LGL leukemia as a clonal disorder characterized by tissue invasion of LGLs in marrow, spleen and liver. Such patients often have chronic neutropenia and splenomegaly, thus meeting clinical criteria for Felty's syndrome. We hypothesize that Felty's syndrome and LGL/RA are the same disease. Multiple lines of evidence, including clinical presentation, immunologic, pathologic and genetic data support this contention. The clinical features of RA occurring in LGL leukemia patients cannot be distinguished from the clinical features of typical RA. A similar effective clinical response to low-dose oral MTX in LGL leukemia patients and Felty's syndrome patients also suggests a common pathogenesis. Pathologic findings in splenectomy specimens are also similar with prominent reactive germinal follicles frequently observed in both conditions. Almost all patients with Felty's syndrome have inherited a DR4 haplotype, and 90% of patients with LGL/RA also have this genetic background. These immunogenetic findings lend further credence to the idea that LGL leukemia with RA and Felty's syndrome are part of the same disease process.
